Skip to main content

Table 2 Accumulation of vanadium (μg/g) in the liver, kidneys, and blood of vehicle-treated, sodium vanadate (SV)-treated, L-ascorbic acid (L-AA)-treated, and L-AA+SV-treated spinal muscular atrophy (SMA) mice

From: Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

Groups

Liver

Kidney

Blood

Postnatal day 6:

   

SMA (vehicle)

ND

ND

 

SMA (SV)

2.11 ± 0.18

3.89 ± 0.60

 

SMA (L-AA)

ND

ND

 

SMA (L-AA+SV)

0.59 ± 0.01 ***

1.37 ± 0.26 *

 

Postnatal day 30:

   

SMA (vehicle)

ND

ND

ND

SMA (L-AA)

ND

ND

ND

SMA (L-AA+SV)

0.22 ± 0.02

0.22 ± 0.04

0.07 ± 0.01

Postnatal day 90:

   

SMA (vehicle)

ND

ND

ND

SMA (L-AA)

ND

ND

ND

SMA (L-AA+SV)

0.08 ± 0.04

0.07 ± 0.02

0.02 ± 0.01

  1. Results are reported as means of three mice in each group ± SEM. *P < 0.05 and ***P < 0.001 relative to SV. ND = not detectable (< 0.202 ng/g).